More recently, Wang et al. explored the efficacy of first-line pemetrexed-based chemotherapy for patients with advanced HER2-mutant lung adenocarcinomas [90]: 29 (5.1%) of patients with HER2 mutations were identified with a shorter median PFS (assessed at 5.1 months) in comparison with the ALK/ROS1 group (p = 0.004). Here, ERBB2 is linked to lung adenocarcinoma.